Skip to main content

Day: September 22, 2024

Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform

MELBOURNE, Australia and INDIANAPOLIS, Ind. and LAKE MARY, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS from its parent company, RLS Group Ltd. The acquisition significantly expands Telix’s North American manufacturing footprint and establishes the basis of a next generation radiometal production network to benefit Telix and select strategic commercial partners. Strategic Rationale The acquisition of RLS is aligned to Telix’s investment strategy around vertically integrated supply chain, manufacturing, and distribution, further enabling the delivery...

Continue reading

Kitron revises outlook for second half 2024

(2024-09-22) Reference is made to the outlook given in Kitron’s second-quarter report. The outlook for Central and Eastern Europe (CEE) sites has not picked up as expected. Several major customers within the market sectors Electrification and Industry have continued to reduce and postpone demand for the third and fourth quarters of 2024 as destocking continues and end markets have not developed as expected.  To facilitate further growth for the Nordic sites, where demand is strong, and stabilize the load for the CEE sites, several product transfers have been planned. Some of these transfers have been pushed to the first half of 2025. For the third quarter, revenues are expected to be between EUR 140 and 150 million with an operating profit (EBIT) between EUR 8 and 10 million.  The full-year 2024 outlook is updated with revenues of between...

Continue reading

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on Monday, September 23, 2024, at 8:00am ET. Webcast information The webcast can be accessed under “Events and Presentations” on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event. About Black Diamond Therapeutics Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies...

Continue reading

Nokia partners with Zain Iraq to boost network capacity with advanced microwave technology

Press ReleaseNokia partners with Zain Iraq to boost network capacity with advanced microwave technology High-capacity microwave solution to enhance network capacity and modernize infrastructure To prepare the network for data surge and increasing network demand 22 September 2024Baghdad, Iraq – Nokia today announced a strategic partnership with Zain Iraq to upgrade the telecom operator’s network in the south of Iraq. The three-year deal marks Nokia’s first entry into the microwave (MW) business with Zain Iraq, enhancing network capacity and modernizing the infrastructure to support future growth and increased traffic demand. The deployment will begin immediately, with a focus on optimizing network performance and ensuring scalability to accommodate future growth. Nokia’s solutions will help Zain Iraq to expand the network capacity...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.